Free shipping on all orders over $ 500

Pacritinib

Cat. No. M2912
Pacritinib  Structure
Synonym:

SB1518

Size Price Availability Quantity
2mg USD 70  USD70 In stock
5mg USD 130  USD130 In stock
10mg USD 230  USD230 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Pacritinib (SB1518) is an effective mutant inhibitor of wild-type JAK2 and JAK2V617F with IC50 of 23 nM and 19 nM, respectively. Pacritinib also inhibited FLT3 and its mutant FLT3D835Y with IC50 of 22 nM and 6 nM, respectively.

Chemical Information
Molecular Weight 472.58
Formula C28H32N4O3
CAS Number 937272-79-2
Form Solid
Solubility (25°C) DMSO 5 mg/mL (Need ultrasonic)
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Annkristin Heine, et al. Pacritinib protects dendritic cells more efficiently than ruxolitinib

[2] Douglas Tremblay, et al. Pacritinib to treat myelofibrosis patients with thrombocytopenia

[3] John Mascarenhas, et al. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

[4] Ruben A Mesa, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

[5] Yan Beauverd, et al. Pacritinib: a new agent for the management of myelofibrosis?

Related JAK Products
A-005

A-005 is a potentially first-in-class, brain-penetrating TYK2 allosteric inhibitor for studies related to neuroinflammatory and neurodegenerative diseases.

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

JAK2/FLT3-IN-1 TFA

JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively.

ZT55

ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC50 value of 0.031 μM.

ZM39923

ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Pacritinib , SB1518 supplier, JAK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.